



中国广西南宁市双拥路6号
No.6 Shuangyong Rd.Nanning,Guangxi,P.R.China
<http://www.gxmu.edu.cn/gxmufyl/index.asp>
E-mail: gxyifuyi@21cn.com
Tel:0086-771-5350895
Fax:0086-771-5350031

广西医科大学第一附属医院
THE FIRST AFFILIATED HOSPITAL OF GUANGXIMEDICAL UNIVERSITY

**FIRST AFFILIATED HOSPITAL of GUANGXI MEDICAL
UNIVERSITY
ETHICAL REVIEW COMMITTEE
Approval Notice**

Approval Number: 2015(KY-E-023)

Title: Human urokinase-type plasminogen activator gene-modified bone marrow-derived mesenchymal stem cells attenuate liver fibrosis in rats by down-regulating the Wnt signaling pathway

Research Contents: The study was undertaken to evaluate the therapeutic effects for liver fibrosis using BMSCs as delivery vehicles with human urokinase-type plasminogen activator (uPA) as therapeutic gene, and to further investigate the underlying mechanism of gene therapy in liver fibrosis rats model.

Applicant: Xiao-Ping Lv

Application Department: Department of Gastroenterology, the First Affiliated Hospital of Guangxi Medical University.

Acknowledgement: This study was supported by supported by grants from the Natural Science Foundation of Guangxi Zhuang Autonomous Region (NO.2012GXNSFAA053143)

Date of Application: 23-July-2015

Date of Approval: 28-July-2015

Conclusion: All experimental procedures of this project were conducted in conformity with institutional guidelines for the care and use of laboratory animals, and the animal use and care protocols were approved by the Committee on Ethical Use of Animals of the Medical Ethics Committee of the First Affiliated Hospital of Guangxi Medical University.

Signature: _____

Lang Li

(Vice) Director of Ethical Review Committee

First Affiliated Hospital of Guangxi Medical University

Date: 28 July, 2015